Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising prevalence of cancer
3.2.1.2 Growing use of radiotheranostics in cancer diagnosis and management
3.2.1.3 Increasing trend of nuclear medicine
3.2.2 Industry pitfalls & challenges
3.2.2.1 Requirement of higher cost for radiotheranostics development
3.2.2.2 Short shelf life of theranostic agents
3.3 Growth potential analysis
3.4 Technological landscape
3.5 Regulatory landscape
3.6 Porter's analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Competitive positioning matrix
4.4 Strategy outlook matrix
Chapter 5 Market Estimates and Forecast, By Radioisotope, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Iodine-131
5.3 Iodine-123
5.4 Gallium-68
5.5 Lutetium-177
5.6. 18F with Y-90
5.7 Other radioisotopes
Chapter 6 Market Estimates and Forecast, By Approach, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Targeted therapeutic
6.3 Targeted diagnostic
Chapter 7 Market Estimates and Forecast, By Application, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Oncology
7.2.1 Thyroid cancer
7.2.2 Neuroendocrine tumors
7.2.3 Hepatocellular carcinoma
7.2.4 Prostate cancer
7.2.5 Other oncology applications
7.3 Non-oncology
7.3.1 Neurological disorders
7.3.2 Arthitis
7.3.3 Other non-oncology applications
Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Italy
8.3.5 Spain
8.3.6 Rest of Europe
8.4 Asia Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.4.6 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Argentina
8.5.3 Mexico
8.5.4 Rest of Latin America
8.6 Middle East and Africa
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
9.1 Life Healthcare Group
9.2 Nordic Nanovector ASA
9.3 Novartis AG
9.4 Progenics Pharmaceuticals, Inc.
9.5 Q BioMed Inc .
9.6 QSAM Biosciences, Inc.
9.7 RadioMedix
9.8 Radiopharm Theranostics Limited
9.9 Telix Pharmaceuticals Limited
9.10 Terumo Corporation
